ICMJE DISCLOSURE FORM

Date:	_2022.11.18	
Your Name	Zhu zhou	
Manuscript	Title: A gene signature driven by abnormally methylated DEGs was developed for TP53 wild-type ovari	an
cancer sam	ples by integrative omics analysis of DNA methylation and gene expression data	
Manuscript	number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	v None	

5	Payment or honoraria for	/ None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	✓ None	
U	testimony	None	
	testimony		
7	Support for attending	✓ None	
,	meetings and/or travel		
8	Patents planned, issued or	/ None	
	pending		
9	Participation on a Data	_ / None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	 None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	/ None	
	materials, drugs, medical		
	writing, gifts or other		
12	services Other financial or non-	. A Nama	
13	financial interests	VNone	
	inialiciai interests		

Please summarize the above conflict of interest in the following box:

The author reports that there are no competing interests to declare.	

Please place an "X" next to the following statement to indicate your agreement:

_ X __ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date:	_2022.11.18
	Hang Jin
Your Name:	
Manuscript ³	Title: A gene signature driven by abnormally methylated DEGs was developed for TP53 wild-type ovaria
cancer samp	ples by integrative omics analysis of DNA methylation and gene expression data
Manuscript	number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the ini	tial planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	/ None	
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
		Time frame: p	ast 36 months
2	Grants or contracts from	/ None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	/ None	

4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus,	None
	manuscript writing or educational events	
6	Payment for expert testimony	
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	/ None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non- financial interests	None
Ple	ease summarize the above c	onflict of interest in the following box:
	The authors report that the	are are no competing interests to declare.

Please place an "X" next to the following statement to indicate your agreement:

_ X __ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date:	_2022.11.18
	Jian Xu
Your Name	·
Manuscript	Title: A gene signature driven by abnormally methylated DEGs was developed for TP53 wild-type ovariar
cancer sam	ples by integrative omics analysis of DNA methylation and gene expression data
Manuscript	number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed) Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	✓ None	

5	Payment or honoraria for	/ None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	✓ None	
U	testimony	None	
	testimony		
7	Support for attending	✓ None	
,	meetings and/or travel		
8	Patents planned, issued or	/ None	
	pending		
9	Participation on a Data	_ / None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	 None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	/ None	
	materials, drugs, medical		
	writing, gifts or other		
12	services Other financial or non-	. A Nama	
13	financial interests	VNone	
	inialiciai interests		

Please summarize the above conflict of interest in the following box:

The authors report that there are no competing interests to declare.	

Please place an "X" next to the following statement to indicate your agreement:

_ X __ I certify that I have answered every question and have not altered the wording of any of the questions on this form.